October 12th, 2022: NCHR strongly recommends that ABRWH encourages NIOSH to reevaluate the risk of radiation exposure to TSA baggage screeners and to take into consideration what workers typically wear during the time of possible exposure for dose reconstruction.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Patient, Consumer, and Public Health Coalition Letter to Senate HELP and Energy and Commerce Committee Regarding User Fee Reauthorization Legislation
September 22, 2022: It is critically important that House and Senate committees work together to consolidate differences between the Food and Drug Amendments Act (H.R. 7667), which passed the House of Representatives on June 8, and the Food and Drug Administration Safety and Landmark Advancements Act (S. 4348), which passed the Senate Health, Education, Labor, and Pensions (HELP) Committee on June 15.
Read More »NCHR’s Comments on the EPA’s Draft Revision for TSCA Risk Determination on Carbon Tetrachloride
September 28, 2022: NCHR strongly supports the EPA’s reconsideration of risk evaluations of carbon tetrachloride using a whole chemical approach. We also strongly endorse the EPA’s decision to exclude the assumption of Personal Protective Equipment (PPE) usage when considering the unreasonable risk of carbon tetrachloride.
Read More »Comment Regarding AHRQ’s Analysis of Requirements for Coverage with Evidence Development (CED) – Topic Refinement
September 28, 2022: NCHR support AHRQ’s overall report and recommendations for the Centers for Medicare and Medicaid Services (CMS) to update their CED requirements.
Read More »Comment of the National Center for Health Research Submitted to the EPA on the Designation of PFOA and PFOS as CERCLA Hazardous Substances, October 6, 2022
October 6, 2022: In our public comment to the EPA, the National Center for Health Research agrees with EPA’s proposed designation of PFOA and PFOS as CERCLA hazardous substances. Holding companies accountable for these toxic chemicals, and other PFAS chemicals, will improve human health.
Read More »